SIM
AKBA icon

Spark Investment Management’s Akebia Therapeutics AKBA Stock Holding History

Spark Investment Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-488,500
Closed -$4M – 558
2019
Q1 		$4M Hold
488,500
– – 0.19% 158
2018
Q4 		$2.7M Buy
488,500
+188,500
+63% +$1.48M 0.19% 159
2018
Q3 		$2.65M Buy
300,000
+24,300
+9% +$217K 0.15% 209
2018
Q2 		$2.75M Sell
275,700
-26,400
-9% -$264K 0.16% 188
2018
Q1 		$2.88M Buy
302,100
+185,700
+160% +$2.6M 0.18% 180
2017
Q4 		$1.73M Buy
116,400
+84,600
+266% +$1.4M 0.09% 291
2017
Q3 		$625K Hold
31,800
– – 0.03% 457
2017
Q2 		$456K Buy
+31,800
New +$403K 0.03% 518
2016
Q4 		– Sell
-51,900
Closed -$469K – 768
2016
Q3 		$469K Buy
+51,900
New +$441K 0.04% 499

Other funds holding AKBA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Spark Investment Management's AKBA Position: Q2 2019 in Review

Spark Investment Management sold out of Akebia Therapeutics (AKBA) in Q2 2019, closing a stake of 488,500 shares — an estimated $4M sold.

Spark Investment Management first reported a position in AKBA in Q3 2016 and held it in 9 quarters. The position peaked at $4M in Q1 2019. 151 funds tracked by Wall St. Rank hold AKBA as of Q2 2019.

  • Spark Investment Management reported no remaining Akebia Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Spark Investment Management sold 488,500 Akebia Therapeutics shares in Q2 2019, an estimated $4M.
  • Spark Investment Management first reported a position in Akebia Therapeutics in Q3 2016 and held it in 9 quarters.
  • Spark Investment Management's Akebia Therapeutics position peaked at $4M in Q1 2019.
  • 151 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2019.

Based on Spark Investment Management's 13F filing for Q2 2019, filed 12 Aug 2019.